## **QUARTERLY STATEMENT**

**OF THE** 

**Athene Annuity and Life Company** 

TO THE

**Insurance Department** 

**OF THE** 

**STATE OF** 

FOR THE QUARTER ENDED MARCH 31, 2019

[ X ] LIFE AND ACCIDENT AND HEALTH

[ ] FRATERNAL BENEFIT SOCIETIES

2019

## **ASSETS**

			Current Statement Date		4
		1 Assets	2 Nonadmitted Assets	3 Net Admitted Assets (Cols. 1 - 2)	December 31 Prior Year Net Admitted Assets
1.	Bonds	37,604,022,335		37,604,022,335	37,954,373,669
	Stocks:				
	2.1 Preferred stocks	121,789,115		121,789,115	121,789,115
	2.2 Common stocks	494,279,210		494,279,210	477,529,433
3.	Mortgage loans on real estate:				
	3.1 First liens	6,479,783,639		6,479,783,639	6,070,077,813
	3.2 Other than first liens	1,672,454,540		1,672,454,540	1,639,441,726
4.	Real estate:				
	4.1 Properties occupied by the company (less \$				
	encumbrances)				
	4.2 Properties held for the production of income (less				
	\$ encumbrances)	9,388,542		9,388,542	9,388,542
	4.3 Properties held for sale (less \$				
	encumbrances)	57,000		57,000	57,000
5.	Cash (\$17,423,302 ), cash equivalents				
	(\$ ) and short-term				
	investments (\$1,824,720,190 )	1,842,143,492		1,842,143,492	1,444,252,897
6.	Contract loans (including \$ premium notes)	188,393,597		188,393,597	189,508,910
7.	Derivatives	744,371,702		744,371,702	749,445,723
8.	Other invested assets			2,054,194,307	1,989,268,742
9.	Receivables for securities	39,385,770		39,385,770	46,185,084
10.	Securities lending reinvested collateral assets				
11.	Aggregate write-ins for invested assets			26,945,866	
12.	Subtotals, cash and invested assets (Lines 1 to 11)	51,277,319,733	110,618	51,277,209,115	50,733,555,231
13.	Title plants less \$ charged off (for Title insurers				
	only)				
14.	Investment income due and accrued	465,464,552	482,239	464,982,313	437,501,299
15.	Premiums and considerations:				
	15.1 Uncollected premiums and agents' balances in the course of collection	4,201		4,201	4 , 123
	15.2 Deferred premiums, agents' balances and installments booked but				
	deferred and not yet due (including \$	0.400.004		0 400 004	0 440 040
	earned but unbilled premiums)	8, 190, 904		8,190,904	8,112,340
	15.3 Accrued retrospective premiums (\$				
40	contracts subject to redetermination (\$ )				
16.	Reinsurance:	101 205 262		181,285,263	211 720 079
	16.1 Amounts recoverable from reinsurers				Z11,730,976
	16.3 Other amounts receivable under reinsurance contracts			1,149,960,582	1 1/8 353 301
17.	Amounts receivable relating to uninsured plans				
	Current federal and foreign income tax recoverable and interest thereon				
	Net deferred tax asset			10,629,157	
19.	Guaranty funds receivable or on deposit				11,689
20.	Electronic data processing equipment and software				.,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
21.	Furniture and equipment, including health care delivery assets				
	(\$				
22.	Net adjustment in assets and liabilities due to foreign exchange rates				
23.	Receivables from parent, subsidiaries and affiliates				428,518
24.	Health care (\$ ) and other amounts receivable			42,598,584	
25.	Aggregate write-ins for other than invested assets			373,351,077	362,530,697
26.	Total assets excluding Separate Accounts, Segregated Accounts and				
	Protected Cell Accounts (Lines 12 to 25)	53,527,307,083	5,818,265	53,521,488,818	52,967,777,787
27.	From Separate Accounts, Segregated Accounts and Protected Cell Accounts	7 023 598 128		7,023,598,128	5,029,174,416
28.	Total (Lines 26 and 27)	60,550,905,211		60,545,086,946	57,996,952,203
	DETAILS OF WRITE-INS	33,000,000,2	0,0.0,200	30,010,000,010	0.,000,002,200
1101.	Derivative Collateral Asset	26 945 866		26,945,866	42 236 577
1101.	Delivative contateral noset			20,943,000	42,200,377
1103.					
1198.	Summary of remaining write-ins for Line 11 from overflow page				
1199.	Totals (Lines 1101 through 1103 plus 1198)(Line 11 above)	26,945,866		26,945,866	42,236,577
2501.	Corporate Owned Life Insurance (COLI)				361,748,235
2502.	Miscellaneous Assets			688,675	782,462
2503.					······································
2598.	Summary of remaining write-ins for Line 25 from overflow page				

## **LIABILITIES, SURPLUS AND OTHER FUNDS**

Aggregate received for this contenting \$ 34,000,000 feets (\$1,700,000 feets)   4,500,000 feets (\$1,700,000 feets)   4,500,		,	1 Current	2 December 31
Missing S				
2 Agropate reserve for excellent and health contracts (including \$ 1,78,518 Motion National). \$1,47,08 \$55,900.  3 and 170,08 \$55,900.  4 Lillie	1.		44 005 636 070	AA 037 658 23A
1. Lichilly for deposed type contracted (mountain)   5.04, 176, 456   Modes Reserve)   288, 77, 989   240, 557, 980   242, 262, 77, 989   242, 262, 262, 262, 262, 262, 262, 262,	2.	Aggregate reserve for accident and health contracts (including \$1,798,678 Modco Reserve)		3,589,927
4 1 Line	3.	Liability for deposit-type contracts (including \$334,718,416 Modco Reserve)	418,417,045	435,597,932
4.2 Accident and health Policyholder dividence/education in members a and oxypor's 3 out 6. Provision for policyholderd dividende, refund is members and casponer payable in following calendar year - extinated annotation 6. Provision for policyholderd dividende and refund to members and casponer payable in following saferodar year - extinated annotation 6. Provision for policyholderd dividende and refunda to members and graptimene (following \$ Mastoo) 6. S. Coupons and smilat serellis (including \$ Modes) 7. Annotation provision of the service of the servic	4.		228 777 939	206 920 090
and urgand  1. Projustorio for prolipholosery' dividends, refunds to members and courson physibile in following calendar year - satimates  1. Prolipholosery' dividends and refunds to members approximated (reclaining 5  1. Prolipholosery' dividends and refunds to members approximated (reclaining 5  1. Prolipholosery' dividends and refunds to members and year approximant (reclaining 5  1. Prolipholosery' dividends the satisfacturing 3  1. Providends and annually considerated and scaletist and health permission.  2. Providend or experience alleging entities, finelding the labelity of \$  2. Providend or experience alleging entities, finelding the labelity of \$  2. Providend or experience alleging entities, finelding the labelity of \$  2. Providend or experience alleging entities, finelding the labelity of \$  3. Ordinate caleting payls for a retires, finelding the labelity of \$  3. Ordinate caleting payls for a retires, finelding the labelity of \$  4. Solid Commissions or experience alleging entities, finelding the labelity of \$  3. Ordinate caleting payls for a retires, finelding the labelity of \$  3. Commissions or experience alleging entities, finelding the labelity of \$  3. Commissions or experience alleging entities, finelding the labelity of \$  3. Translated by agree the and annually contained \$  3. Translated by agree the and annually contained \$  4. To see the second payls of the retirements assumed  3. Translated by agree the and annually contained \$  4. Translated by agree the angular payls of the retirement and the annual payls of the retirement and the annual payls of the annual payls				
5. Provision to policyhodred vidusinda, refunda to membars and couptors payable in following claimidar year - estimated amounts.  Modes)  A Delicyhodred vidusinda and refunda to membars apportroad romania (Modes)  1. 2. Policyhodred vidusinda and refunda to membars a rey al apportroad romania (Modes)  1. 2. Policyhodred vidusinda and refunda to membars are yell apportroad romania (Modes)  1. 2. Policyhodred vidusinda and refunda to membars are yell apportroad romania (Modes)  2. 3. Premistra and amutu yo completariosis to file and accorded and health controllate social en abdunce less 3 5.599 accident and health permistras (Modes)  3. Premistra and amutu yo completariosis to file and accorded and health permistras (Modes)  3. Premistra and amutu yo completariosis to file and accorded and health permistras (Modes)  3. Premistra and amutu yo completariosis to file and accorded and health permistras (Modes)  3. Premistra and amutu yo completariosis to file and accorded and health permistras (Modes)  3. Premistra and amutu your permistras (Modes)  4. Premistra and amutu your permistras (Modes)  5. Premistras and permistras (Modes)  6. In 1990 1990 1990 1990 1990 1990 1990 199	5.			
erroutis 6. Polity-holders dividends and refunds to members approfound for payment (including \$ 6. Polity-holders dividends and refunds to members ray preparational for payment (including \$ 7. Amount provisionally had to desire a dividend of polity apportunity of the first of t	6.			
Models) A Polity-incident dividends and relunds to members not yet apportioned including \$ Notice)  5 Polity-incident dividends and relunds to members not yet apportioned including \$ Notice)  7 Polity-incident dividends and relunds of the Models  8 Secretary of the Common of the Common of the Models of the Models  9 Secretary of the Models  9 Secretary of the Models of the Mode		amounts:		
6. 2 Policytockers dividuals and edurates to membrars not yet apportioned involving \$ 6. 53. Course and shalls benefit priciously \$ 7. Amount provisionally held to defend butter and shall in the membrars of the provisional				
7. Amount provisionally held for defend dividend policies not included in Line 6 Persilium and annully condectable for the data doctor at health concess received in advance less  9. Provision of annully condectable for the data doctor at health promisers  9. Provision for experiments rating refunds, including the fability of 8 9. Summed values on cancello down with 5 is for modicel bees rato receive the per the Public Health  9. Shared values on cancello down with 5 is for modicel bees rato receive the per the Public Health  9. Shared values on cancello down with 5 is for modicel bees rato receive the per the Public Health  9. Shared values on cancello developed the per the Public Health  9. Shared values on cancello developed the per the Public Health  9. Shared values on cancello developed the per the Public Health  9. Shared values on cancello developed the per the Public Health  9. Shared values on cancello developed the per the Public Health  9. Shared values on cancello developed the per the Public Health  9. Shared values on cancello developed the per the per the per the Public Health  9. Shared values on cancello developed the per t		6.2 Policyholders' dividends and refunds to members not yet apportioned (including \$ Modco)		
8. Permuns and annuis prosidentations for lite and accordent are cheated in advancer less \$ 3 months and annuis prosidents (including \$ 5,99 accident and health experience rating relativals of which \$ contact lisabilities and included elevatives.  9.2 Provision for experience relating relativals (including the lizability of \$ contact lisabilities and relative species and support services and support services and support services.  9.2 Provision for experience relating relativals (including the lizability of \$ contact services and se	7			
9. Command facilities not included elemenhance 9.1 Summonder values on canadactic contracts 9.1 Summonder values on canadactic contracts 9.2 Summonder values on canadactic contracts 9.3 Summonder values on canadactic contracts 9.3 Other amounts peapled on reinsurance including \$ assumed and \$ 1,780,194,490 9.5 Other amounts peapled on reinsurance including \$ assumed and \$ 1,780,194,490 9.5 Other amounts peapled on reinsurance including \$ assumed and \$ 1,780,194,490 9.5 Other amounts peapled on reinsurance including \$ 12,817,741 , accident and health 9.5 Summonder of the contract of the contract funds \$ 12,817,741 , accident and health 9.5 Summonder of the contract funds \$ 12,817,741 , accident and health 9.5 Summonder of the contract funds \$ 12,817,741 , accident and health 9.5 Summonder of the contract funds \$ 12,817,741 , accident and health 9.5 Summonder of the contract funds \$ 1,155,000 9.5 Summonder of the contract funds \$		Premiums and annuity considerations for life and accident and health contracts received in advance less		
9.1   Surrendor values on cancelled contracts   2.2			5,999	4,505
9.2 Provision for experience rating returds, including the liability of \$   accident and health experience rating returds of which \$   is for medical loss ratio better per the Public Health Service Act.	9.			
Service Act		9.2 Provision for experience rating refunds, including the liability of \$ accident and health		
9.3 Other amounts pepale on reinsurance, including \$ assumed and \$ 1,780,019,450   1,956,144,225   1,956,144,225   1,170,019,450   1,956,144,225   1,170,019,450   1,170,450   1				
9.4 Interest Maintenance Reserve 1.15, 416, 045 1.15, 293, 154 1.1				
10. Commissions to agents due or accrued life and annuity contracts \$ 2,2,837,741   1,155,001				
\$ and deposit-type contract funds \$	10.	Commissions to agents due or accrued-life and annuity contracts \$ 12 831 741 accident and health	, ,	, ,
1.1. Commissions and expense allowances payable on reinsurance assumed   17,114,09		\$ and deposit-type contract funds \$	12,831,741	11, 155,010
13. Transfers to Separate Accounts due or accrued (not) (including \$ allowance recognized in reversive, not of reinsured allowances)   1,046,049,277   1,050,112,530   13.80	I	Commissions and expense allowances payable on reinsurance assumed	17 11/ 900	14 547 405
allowances recognized in reserves, net of reinsured allowances   1,040,049,277   1,1050,112,514   Taxes, licenses and fees due or acroused, excluding \$   13,800   41,595,151   13,900   41,595,151		Transfers to Separate Accounts due or accrued (net) (including \$(153) accrued for expense		
15.1   Current federal and foreign income taxes, including \$   0.00		allowances recognized in reserves, net of reinsured allowances)		
15.2 Net deferred tax liability		Taxes, licenses and fees due or accrued, excluding federal income taxes	13,800	41.259.937
17. Amounts withheld or retained by reporting entity as agent or frustee   1,865,920   2,231,485     18. Amounts held for agents's coordinated   170,646,687   157,657,507     19. Remittances and items not allocated   170,646,687   157,657,507     21. Liability for benefits for employees and agents if not included above   9,79,540   42,899,867     22. Borrower money \$   3   14,899,867   14,899,867     23. Dividends to stockholders declared and unpaid   14,899,867   14,899,867     24. Mecelleracus liabilities   24,401 Asset valuation reserve   661,801,607   644,533,822   24,02 Remissance in unauthorized and certified (\$ ) companies   1,407,686,614   1,411,232,744   24,04 Fayable to parents, ubsclainces and affiliates   1,402,314   24,04 Fayable to parents, ubsclainces and affiliates   14,025,314   24,04 Fayable to parents, ubsclainces and affiliates   14,025,314   24,04 Fayable to parents, ubsclainces and affiliates   24,05 Dratts outstanding   24,06 Liability for amounts held under uninsured plans   24,07 Funds held under coinsurance   25,359,322   39,483,431   24,04 Payable for securities   36,262,750   2,132,984   24,10 Payable for securities ending   24,10 Payable for securities   25,269,750   27,132,984   24,10 Payable for securities   25,269,750   27,132,984   24,10 Payable for securities ending   24,10 Payable for securities   25,269,750   27,100,000   27,000,000		Net deferred tax liability		
18. Amounts held for agents' account, including \$ 2,423,038 agents' credit balances   2,423,038   3,597,955     19. Remittances and idensine to allocated   170,646,587   157,645,700     20. Not adjustment in assets and liabilities due to foreign exchange rates   979,540   .42,899,660     22. Borrowed money \$	-	Unearned investment income	3,112,228	3,020,170
19. Remittances and items not allocated   170, 645, 587   557, 557, 550		Amounts held for agents' account, including \$	2,423,038	3,597,955
1.1 Liability for benefits for employees and agents if not included above	19.	Remittances and items not allocated	170,646,587	157,657,501
Borrowed money \$				
Miscellaneous liabilities:   24.01 Asset valuation reserve   24.02 Reinsurance in unauthorized and certified (\$ ) companies   1,407,698,614   1,411,232,746   24.04 Payable to parent, subsidiaries and affiliates   19,948,581   14,025,316   24.05 Payable to parent, subsidiaries and affiliates   19,948,581   14,025,316   24.05 Payable to parent, subsidiaries and affiliates   24.05 Payable to parent, subsidiaries   24.05 Parent sustanding   24.05 Parent sustanding   24.05 Parent substanding   24.05 Paren				
24.01 Asset valuation reserve		•		
24.02 Reinsurance in unauthorized and certified (\$ ) companies 24.03 Proubs held under reinsurance treatises with unauthorized and certified (\$ ) reinsurers 1, 407, 696, 614 24.04 Payable to parent, subsidiaries and affiliates 24.05 Itability for amounts held under uninsured plans 24.06 Liability for amounts held under uninsured plans 24.07 Prunds held under coinsurance 24.08 Derivatives 24.09 Derivatives 24.09 Payable for securities 24.09 Payable for securities 24.10 Payable for securities lending 24.11 Capital notes \$ and interest thereon \$ 1,978,00,381,382,370 24.10 Payable for securities lending 24.11 Capital notes \$ 1,978,00,381,381,382,380 25. Aggregate write-ins for liabilities 37. Total liabilities excluding Separate Accounts business (Lines 1 to 25) 38. Total liabilities (Lines 26 and 27) 39. 27. Total liabilities (Lines 26 and 27) 39. 27. Total liabilities (Lines 26 and 27) 39. 27. Total liabilities (Lines 26 and 27) 39. 28. Total liabilities (Lines 26 and 27) 39. 28. Total liabilities (Lines 26 and 27) 39. 29. Common capital stock 30. Preferred capital stock 30. Preferred capital stock 31. Aggregate write-ins for other than special surplus funds 32. Surplus notes 33. Gross paid in and contributed surplus 34. Aggregate write-ins for special surplus funds 35. Unassigned funds (surplus) 36. Less treasury stock, at cost: 36.1	24.		661,801,607	644,533,824
24.04 Payable to parent, subsidiaries and affiliates		24.02 Reinsurance in unauthorized and certified (\$		
24.05 Drafts outstanding. 24.06 Leability for amounts held under uninsured plans 24.07 Funds held under coinsurance 24.08 Derivatives 24.08 Payable for securities 24.10 Payable for securities lending 25. Aggregate write-ins for flabilities 26. Total liabilities exclusing Separate Accounts business (Lines 1 to 25) 27. From Separate Accounts Statement 28. Total liabilities exclusing stock 29. Common capital stock 20. Total liabilities (Lines 26 and 27) 29. Perferred capital stock 20. Surplus notes 20. Surplus not		24.03 Funds held under reinsurance treaties with unauthorized and certified (\$	1,407,696,614	1,411,232,746
24.07 Funds held under coinsurance 24.09 Payable for securities 24.09 Payable for securities 24.10 Payable for securities lending 24.11 Capital notes \$ and interest thereon \$ 24.11 Capital notes \$ and interest thereon \$ 25. Aggregate write-ins for liabilities 25. Total liabilities excluding Separate Accounts business (Lines 1 to 25) 27. From Separate Accounts Statement 28. From Separate Accounts Statement 29. From Separate Accounts Statement 29. Common capital stock 29. Common capital stock 20. Preferred capital stock 20. Preferred capital stock 20. Preferred capital stock 21. Aggregate write-ins for other than special surplus funds 22. Surplus notes 23. Surplus notes 24. Aggregate write-ins for special surplus funds 25. Surplus notes 26. Less treasury stock, at cost: 26. Less treasury stock, at cost: 27. Surplus (Total Lines 31+32+33+43+35-36) (including \$		24.05 Drafts outstanding		
24.08 Derivatives				
24.10 Payable for securities lending.       24.11 Capital notes \$       1.597.880.391       940.220.425         25. Aggregate write-ins for liabilities.       1.597.880.391       940.220.425         26. Total liabilities excluding Separate Accounts business (Lines 1 to 25).       52,594.764.075       52,053.109.68         27. From Separate Accounts Statement.       6,702.371.417       4,709.678.89         28. Total liabilities (Lines 26 and 27).       59.297.135.493       56,702.788.30         29. Common capital stock.       10,000,000       10,000,000         30. Preferred capital stock.       10,000,000       10,000,000         31. Aggregate write-ins for other than special surplus funds       953.662,345       952.052.245         32. Surplus notes       953.662,345       952.052.245         33. Gross paid in and contributed surplus       953.662,345       952.052.245         34. Aggregate write-ins for special surplus funds       224,289,108       277,111,580         35. Unassigned funds (surplus)       953.662,345       952.052.245         36. Less treasury stock, at cost:       36.1       shares preferred (value included in Line 90 \$ )       )       227,111,580         36. Surplus (Total Lines 31+32+3344-345-356) (including)       32,225,711       in Separate Accounts Statement)       1,237,951,453       1,247,163,622         3		24.08 Derivatives	25,359,322	39,463,437
24.11 Capital notes \$ and interest thereon \$				
25. Aggregate write-ins for liabilities excluding Separate Accounts business (Lines 1 to 25) 27. From Separate Accounts Statement 28. Total liabilities (Lines 26 and 27) 28. Total liabilities (Lines 26 and 27) 29. Common capital stock 20. Common capital stock 30. Preferred capital stock 31. Aggregate write-ins for other than special surplus funds 32. Surplus notes 33. Gross paid in and contributed surplus. 34. Aggregate write-ins for special surplus funds 35. Less treasury stock, at cost: 36. 1 shares common (value included in Line 29 \$ ) 36. Less treasury stock, at cost: 36. 1 shares common (value included in Line 29 \$ ) 37. Surplus (Total Lines 31+32+33+34+35-36) (including \$321,226,711 in Separate Accounts Statement) 39. Totals of Lines 29, 30 and 37 31. Totals of Lines 28 and 38 (Paga 2, Line 28, Col. 3) 39. Totals of Lines 28 and 38 (Paga 2, Line 28, Col. 3) 39. DETAILS OF WRITE-INS 2501. Derivative Collateral Liability 40. 2504. Amount Due Reinsurer 40. 37. House 26 and 38 (Paga 2, Line 28, Col. 3) 40. DETAILS OF WRITE-INS 2502. Amount Due Reinsurer 40. 37. Oil 1, 257, 880, 391 40. 303, 304 405. Summary of remaining write-ins for Line 31 from overflow page 40. 250. Amount Due Reinsurer 40. 37. Oil 1, 257, 880, 391 40. 309. Summary of remaining write-ins for Line 31 from overflow page 40. 250. Month Due Reinsurer 40. 37. Oil 1, 266, 582 480. Summary of remaining write-ins for Line 31 from overflow page 50. Summary of remaining write-ins for Line 31 from overflow page 50. Summary of remaining write-ins for Line 31 from overflow page 50. Summary of remaining write-ins for Line 31 from overflow page 50. Summary of remaining write-ins for Line 34 from overflow page 50. Summary of remaining write-ins for Line 34 from overflow page 50. Summary of remaining write-ins for Line 34 from overflow page 50. Summary of remaining write-ins for Line 34 from overflow page 50. Summary of remaining write-ins for Line 34 from overflow page 50. Summary of remaining write-ins for Line 34 from overflow page				
From Separate Accounts Statement	l l	Aggregate write-ins for liabilities	1,597,880,391	940,230,423
Total liabilities (Lines 26 and 27)				
29. Common capital stock			59,297,135,493	56,762,788,380
31. Aggregate write-ins for other than special surplus funds		Common capital stock	10,000,000	
Surplus notes   Surplus notes   Sicros paid in and contributed surplus   953,662,345   952,052,245   952,052,245   952,052,245   952,052,245   952,052,245   952,052,245   952,052,245   952,052,245   953,662,345   952,052,245   953,662,345   952,052,245   953,662,345   952,052,245   953,662,345   952,052,245   953,662,345   952,052,245   953,662,345   952,052,245   953,662,345   952,052,245   953,662,345   953,662,345   952,052,245   953,662,345		·		
34. Aggregate write-ins for special surplus funds 35. Unassigned funds (surplus). 36. Less treasury stock, at cost: 36.1 shares common (value included in Line 29 \$ 36.2 shares preferred (value included in Line 30 \$ 37. Surplus (Total Lines 31+32+33+34+35-36) (including \$ 38. Totals of Lines 29, 30 and 37. 39. Totals of Lines 29, 30 and 37. 30. Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3)  DETAILS OF WRITE-INS  Derivative Collateral Liability  Derivative Collateral Liability  Amount Due Reinsurer  37, 011, 206  39, 396, 002  2503. Unclaimed Funds  Summary of remaining write-ins for Line 25 from overflow page  52599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)  3101. 3102. 3103. 3103. 3104. 3403. 3498. Summary of remaining write-ins for Line 34 from overflow page  Summary of remaining write-ins for Line 34 from overflow page  Summary of remaining write-ins for Line 34 from overflow page  Summary of remaining write-ins for Line 34 from overflow page  Summary of remaining write-ins for Line 34 from overflow page  Summary of remaining write-ins for Line 34 from overflow page  Summary of remaining write-ins for Line 34 from overflow page  Summary of remaining write-ins for Line 34 from overflow page  Summary of remaining write-ins for Line 34 from overflow page	32.	Surplus notes		
35. Unassigned funds (surplus)				
36.1 shares common (value included in Line 29 \$ ) 36.2 shares preferred (value included in Line 30 \$ ) 36.2 shares preferred (value included in Line 30 \$ ) 37. Surplus (Total Lines 31+32+33+34+35-36) (including \$		99 9	284,289,108	272,111,580
36.2 shares preferred (value included in Line 30 \$ )	36.			
37. Surplus (Total Lines 31+32+33+34+35-36) (including \$				
39. Totals of Lines 28 and 38 (Page 2, Line 28, Col. 3)  DETAILS OF WRITE-INS  2501. Der ivat ive Collateral Liability 2502. Amount Due Reinsurer 2503. Unclaimed Funds 2509. Summary of remaining write-ins for Line 25 from overflow page 2509. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above) 2509. Totals (Lines 3101 through 3103 plus 3198)(Line 31 above) 2509. Totals (Lines 3101 through 3103 plus 3198)(Line 31 above) 2509. Totals (Lines 3101 through 3103 plus 3198)(Line 31 above) 2509. Totals (Lines 3101 through 3103 plus 3198)(Line 31 above) 2509. Summary of remaining write-ins for Line 31 from overflow page 2509. Totals (Lines 3101 through 3103 plus 3198)(Line 31 above) 2509. Totals (		Surplus (Total Lines 31+32+33+34+35-36) (including \$321,226,711 in Separate Accounts Statement)	1,237,951,453	1,224,163,823
DETAILS OF WRITE-INS   2501.   Derivative Collateral Liability   1,523,142,195   875,837,195   2502.   Amount Due Reinsurer   37,011,206   30,396,002   2503.   Unclaimed Funds   32,474,686   32,840,690   2598.   Summary of remaining write-ins for Line 25 from overflow page   5,252,304   1,156,536   2599.   Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)   1,597,880,391   940,230,423   3101.   3102   3103   3103   3103   3103   3103   3103   3103   3103   3103   3103   3103   3104   3105			, , ,	
2501.       Derivative Collateral Liability       1,523,142,195       875,837,195         2502.       Amount Due Reinsurer       37,011,206       30,396,002         2503.       Unclaimed Funds       32,474,686       32,840,690         2598.       Summary of remaining write-ins for Line 25 from overflow page       5,252,304       1,156,536         2599.       Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)       1,597,880,391       940,230,423         3101.       3102.       3103	39.		00,040,060,940	J1,380,352,203
2503. Unclaimed Funds       32,474,686       32,840,690         2598. Summary of remaining write-ins for Line 25 from overflow page       5,252,304       1,156,536         2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)       1,597,880,391       940,230,423         3101.       3102.       3103.       3109.       3103.       3109.       3103.       3109.       3103.       3109.       3103.       3109.       3103.       3109.       3103.       3109.	1			875,837,195
2598. Summary of remaining write-ins for Line 25 from overflow page       .5,252,304       .1,156,536         2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)       1,597,880,391       940,230,423         3101.	1			
2599. Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)       1,597,880,391       940,230,423         3101.       3102.       3103.       3103.       3103.       3103.       3103.       3104.       3105.       3106.       3106.       3106.       3107.       3108.       3109.		Summary of remaining write-ins for Line 25 from overflow page	5,252,304	1, 156, 536
3102.       3103.         3198.       Summary of remaining write-ins for Line 31 from overflow page		Totals (Lines 2501 through 2503 plus 2598)(Line 25 above)	1,597,880,391	940,230,423
3103.       3198.       Summary of remaining write-ins for Line 31 from overflow page	1			
3199. Totals (Lines 3101 through 3103 plus 3198)(Line 31 above)	3103.			
3401.       3402.         3403.       3403.         3498.       Summary of remaining write-ins for Line 34 from overflow page		, a		
3403. Summary of remaining write-ins for Line 34 from overflow page				
3498. Summary of remaining write-ins for Line 34 from overflow page	I			
, ,				
ייסני ייסני ווויטעקוו טייסט אונט אונט טייסט אונט טייסט אונט טייסט אונט טייסט אונט אונט טייסט אייסט אונט טייסט אונט טייסט אונט טייסט אייסט אייט איי	3499.	Totals (Lines 3401 through 3403 plus 3498)(Line 34 above)		

## **SUMMARY OF OPERATIONS**

		1 1	2	3
		Current Year	Prior Year	Prior Year Ended
		To Date	To Date	December 31
1.	Premiums and annuity considerations for life and accident and health contracts	566,043,209	186,594,540	1,272,542,499
2.	Considerations for supplementary contracts with life contingencies.	345,510	788,733	2,084,517
3.			912,569,868	3,331,541,787
4.	Amortization of Interest Maintenance Reserve (IMR)		3,009,675	12,526,969
5.	Separate Accounts net gain from operations excluding unrealized gains or losses			(1,793,871)
6.	Commissions and expense allowances on reinsurance ceded	203,395,087	179,593,954	843,875,751
7.	Reserve adjustments on reinsurance ceded	(412,659,961)	(449,898,267)	(1,239,157,364)
8.	Miscellaneous Income:			
	8.1 Income from fees associated with investment management, administration and contract	4 000 057	4 070 405	0.050.004
	guarantees from Separate Accounts.		1,9/3,465	9,358,934
	8.2 Charges and fees for deposit-type contracts			
	8.3 Aggregate write-ins for miscellaneous income		4,186,524	14,969,049
	Totals (Lines 1 to 8.3)	959,338,160	838,408,108	4,245,948,272
	Death benefits		356,739	1,912,216
11.	Matured endowments (excluding guaranteed annual pure endowments)			
12.	Annuity benefits	67,912,345	67,374,137	237, 185, 461
13.	Disability benefits and benefits under accident and health contracts			465,384
14.	Coupons, guaranteed annual pure endowments and similar benefits			
15.	Surrender benefits and withdrawals for life contracts		141,952,989	645,170,390
16.	Group conversions		0.050.500	47.000.504
17.	Interest and adjustments on contract or deposit-type contract funds	3,739,729	6,056,526	17,022,504
18.	Payments on supplementary contracts with life contingencies	2,300,682		8,976,427
	Increase in aggregate reserves for life and accident and health contracts		306,325,916	1,697,817,747
20.	Totals (Lines 10 to 19)	318,004,163	524,355,292	2,608,550,128
21.	Commissions on premiums, annuity considerations, and deposit-type contract funds (direct	154 405 045	100 407 000	CEO EE4 004
	business only)	105,915	123,467,398	658,551,984
22.	Commissions and expense allowances on reinsurance assumed		72,548	689,230
23.	General insurance expenses and fraternal expenses		65,194,207	274,366,758 5,483,850
24.	Insurance taxes, licenses and fees, excluding federal income taxes	5,223,161	15,989,111	
25.	Increase in loading on deferred and uncollected premiums	(2)	40 743 401	2
26.	Net transfers to or (from) Separate Accounts net of reinsurance			464,892,550
27.	Aggregate write-ins for deductions	27,645,185	12,081,715	60,951,265
28.	Totals (Lines 20 to 27)	937, 173, 610	783,901,761	4,073,485,768
29.	Net gain from operations before dividends to policyholders and federal income taxes (Line 9 minus	00 104 540	E4 E06 047	170 460 504
00	Line 28)	22,164,549	54,506,347	172,462,504
30.	Dividends to policyholders and refunds to members	1,612	(490)	
31.	Net gain from operations after dividends to policyholders, refunds to members and before federal income taxes (Line 29 minus Line 30)	22,162,938	54,506,837	172,462,504
32.	Federal and foreign income taxes incurred (excluding tax on capital gains)	(17,948,699)	(4,773,986)	19,768,341
33.	Net gain from operations after dividends to policyholders, refunds to members and federal income	(17,340,033)	(4,770,300)	13,700,041
33.	taxes and before realized capital gains or (losses) (Line 31 minus Line 32)	40 111 637	59,280,823	152,694,163
34.	Net realized capital gains (losses) (excluding gains (losses) transferred to the IMR) less capital		00,200,020	102,004,100
04.	gains tax of \$			
	transferred to the IMR)	(3,580,836)	(33,761,394)	(72.058.940)
35.	Net income (Line 33 plus Line 34)	36.530.800	25.519.429	80.635.223
00.	CAPITAL AND SURPLUS ACCOUNT	00,000,000	20,010,420	00,000,220
26		1,234,163,823	1,164,208,655	1,164,208,655
36. 37.	Capital and surplus, December 31, prior year		25,519,429	80,635,223
38.	Change in net unrealized capital gains (losses) less capital gains tax of \$(1, 121,072)			75,011,017
	Change in net unrealized capital gains (losses) less capital gains tax or \$(1, 121,072)  Change in net unrealized foreign exchange capital gain (loss)			4.443.959
	Change in net deferred income tax	(0, 972, 740)	17 617 227	53,029,808
40.	Change in neg deferred income tax	(9,073,740)	17,017,227	
41.	Change in nonadmitted assets  Change in liability for reinsurance in unauthorized and certified companies	941,000	(8,363,023)	(201, 140)
42.	,			
43.	Change in reserve on account of change in valuation basis, (increase) or decrease	(17 067 700)	(20, 022, 764)	(02 CO0 OCE)
44.	Change in asset valuation reserve			
45.	Change in treasury stock			
46.	Surplus (contributed to) withdrawn from Separate Accounts during period	404 000	(100 F01)	(1/3,/83,018)
	Other changes in surplus in Separate Accounts Statement			
48.	Change in surplus notes			
49.	Cumulative effect of changes in accounting principles			
50.	Capital changes:			
	50.1 Paid in			
	50.2 Transferred from surplus (Stock Dividend)			
F.4	50.3 Transferred to surplus	<b></b>		
51.	Surplus adjustment:	4 640 400	0.070.000	04 070 040
1	51.1 Paid in			
	51.2 Transferred to capital (Stock Dividend)			
	51.3 Transferred from capital	4 054 040	(04 404 047)	(20, 150, 275)
	51.4 Change in surplus as a result of reinsurance			
	Dividends to stockholders			(FO 140 44C)
	Aggregate write-ins for gains and losses in surplus			(53, 149, 446)
	Net change in capital and surplus for the year (Lines 37 through 53)		19,023,298	69,955,168
55.	Capital and surplus, as of statement date (Lines 36 + 54)	1,247,951,453	1,183,231,953	1,234,163,823
1	DETAILS OF WRITE-INS		==	
	COLI Income			15, 120,314
	Miscellaneous (Expense) Income	(62,852)	,	(151,265)
	Summary of remaining write-ins for Line 8.3 from overflow page			44 000 040
	Totals (Lines 08.301 through 08.303 plus 08.398) (Line 8.3 above)	10,851,316	4,186,524	14,969,049
2701.	Funds Withheld Adjustment - Ceded	27,247,220		93,685,207
	Transfer to IMR - Ceded			(36,752,804)
	Transfer to IMR - MVA Benefits		,	
	Summary of remaining write-ins for Line 27 from overflow page		4,533	165, 181
	Totals (Lines 2701 through 2703 plus 2798)(Line 27 above)	27,645,185	12,081,715	60,951,265
	Correction of Prior Period Error		(21,307,811)	
	Athene Re IV Tax Sharing Agreement		77,961	1, 113, 179
5398.	Summary of remaining write-ins for Line 53 from overflow page			
	Totals (Lines 5301 through 5303 plus 5398)(Line 53 above)	(2,351,821)	(21,229,850)	(53, 149, 446)
		<u></u>		

## **CASH FLOW**

		Current Year To Date	Prior Year To Date	Prior Year Ended December 31
	Cash from Operations			
1.	Premiums collected net of reinsurance	566,404,842	187,453,840	1,275,400,217
2.	Net investment income	539,672,485	875,008,085	3,214,717,260
3.	Miscellaneous income	215,160,109	185,573,477	866,096,824
4.	Total (Lines 1 to 3)	1,321,237,435	1,248,035,402	5,356,214,30
5.	Benefit and loss related payments	658,617,580	595,289,926	1,873,258,75
6.	Net transfers to Separate Accounts, Segregated Accounts and Protected Cell Accounts	364 , 130 , 425	(34, 160, 371)	86 , 153 , 558
7.	Commissions, expenses paid and aggregate write-ins for deductions	223,733,183	197,682,096	935,550,51
8.	Dividends paid to policyholders	1,612	(490)	
9.	Federal and foreign income taxes paid (recovered) net of \$16,411,246 tax on capital			
	gains (losses)	41,259,936	(18,611,933)	5,772,89
10.	Total (Lines 5 through 9)	1,287,742,736	740,199,227	2,900,735,73
11.	Net cash from operations (Line 4 minus Line 10)	33,494,699	507,836,175	2,455,478,57
	,	, ,	, ,	
10	Cash from Investments			
12.	Proceeds from investments sold, matured or repaid:	1 005 000 000	4 057 700 700	7 000 005 70
	12.1 Bonds			
	12.2 Stocks			
	12.3 Mortgage loans			
	12.4 Real estate			
	12.5 Other invested assets			
	12.6 Net gains or (losses) on cash, cash equivalents and short-term investments			3,01
	12.7 Miscellaneous proceeds	84,020,395	282,583,205	41,677,51
	12.8 Total investment proceeds (Lines 12.1 to 12.7)	1,663,415,553	2,611,964,969	8,750,071,368
13.	Cost of investments acquired (long-term only):			
	13.1 Bonds	1,117,903,969	2,719,453,135	6,960,019,37
	13.2 Stocks		23,658,756	104,335,09
	13.3 Mortgage loans	625,747,561	402,503,658	3,755,618,11
	13.4 Real estate			
	13.5 Other invested assets	150,778,789	116,971,769	447,528,618
	13.6 Miscellaneous applications	9,490,287	81,751,280	223,383,953
	13.7 Total investments acquired (Lines 13.1 to 13.6)	1,903,920,606	3,344,338,598	11,490,885,147
14.	Net increase (or decrease) in contract loans and premium notes	(1,115,313)	(5,000,178)	(20,498,339
15.	Net cash from investments (Line 12.8 minus Line 13.7 and Line 14)	(239,389,739)	(727,373,451)	(2,720,315,44
10	Cash provided (applied):			
16.	Cash provided (applied):			
	16.1 Surplus notes, capital notes			
	16.2 Capital and paid in surplus, less treasury stock			
	16.3 Borrowed funds			
	16.4 Net deposits on deposit-type contracts and other insurance liabilities			
	16.5 Dividends to stockholders			
	16.6 Other cash provided (applied)	620,966,523	(1,135,215,374)	(1,380,786,420
17.	Net cash from financing and miscellaneous sources (Line 16.1 through Line 16.4 minus Line 16.5 plus Line 16.6)	603,785,635	(1, 156, 179, 154)	(1,467,010,454
	RECONCILIATION OF CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS			
18.	Net change in cash, cash equivalents and short-term investments (Line 11, plus Lines 15 and 17)	397,890,595	(1,375,716,429)	(1 731 847 32
19.	Cash, cash equivalents and short-term investments:		(1,070,710,120)	(1,701,017,02
13.	19.1 Beginning of year	1,444,252,897	3, 176, 100, 220	3 176 100 22
				1,444,252,89
	19.2 End of period (Line 18 plus Line 19.1)	1,842,143,492	1,800,383,791	1,444,202,69
	upplemental disclosures of cash flow information for non-cash transactions:	4 040 400	0.070.000	0.070.07
	01. Capital contribution of stock compensation expense (financing)		2,379,693	9,072,91 (691,94
0.000	03. Capital contribution of stock compensation expense (operating)	(1,481,136)	(2,249,997)	(8,380,96
	04. Reinsurance activity settled in bonds (operating)			
0.000	06. Security exchanges and asset in kind trades - bond proceeds (investing)	58,212,697	60,255,556	1, 156, 632, 17
	07. Security exchanges and asset in kind trades — bonds acquired (investing) 08. Interest capitalization (operating)			
	09. Interest capitalization (operating)			
	10. Transfer from Schedule B to Schedule BA - proceeds (investing)			

# STATEMENT AS OF MARCH 31, 2019 OF THE Athene Annuity and Life Company res of cash flow information for non-cash transactions:

Note: Supplemental disclosures of cash flow information for non-cash transactions:		
20.0011. Transfer from Schedule B to Schedule BA - acquired (investing)	(16,318)	 (94,300)
20.0012. Security exchanges and asset in kind trades - mortgage loans acquired (investing)		 (153,616,009)
20.0013. Security exchanges and asset in kind trades - other invested assets acquired (investing)		
		 (52,816,500)
20.0014. Security exchanges and asset in kind trades - stock proceeds (investing)		 17,710,008
20.0015. Security exchanges and asset in kind trades - stocks acquired (investing)		 (17,710,008)
20.0016. Schedule BA distribution - proceeds (investing)		 8,894,137
20.0017. Schedule BA distribution - acquired (investing)		 (8,894,137)
20.0018. Capital contribution (financing)		 15,000,000
20.0019. Capital contribution - stocks acquired (investing)		 (15,000,000)

#### Note 1. Summary of Significant Accounting Policies and Going Concern

#### A. Accounting Practices

The accompanying financial statements of **Athene Annuity and Life Company** (the Company) have been prepared in conformity with the accounting practices prescribed or permitted by the National Association of Insurance Commissioners (NAIC) and the State of Iowa.

The Insurance Division, Department of Commerce, of the State of Iowa (the Division) recognizes only statutory accounting practices prescribed or permitted by the State of Iowa for determining and reporting the financial condition and results of operations of an insurance company and for determining its solvency under the Iowa Insurance Law. The NAIC's Accounting Practices & Procedures Manual (NAIC SAP) has been adopted as a component of prescribed or permitted practices by the State of Iowa. The Commissioner of Insurance has the right to permit other specific practices that deviate from prescribed practices.

Among the products issued by the Company are indexed universal life insurance and indexed annuities. These products allow a portion of the premium to earn interest based on certain indices, primarily the Standard & Poor's 500 Composite Stock Price Index. Call options, futures, variance swaps and total return swaps are purchased to hedge the growth in interest credited to the customer as a direct result of increases in the related indices. In 2006, the Commissioner of the Division issued Bulletin 06-01, Accounting for Derivative Instruments Used to Hedge the Growth in Interest Credited for Index Products, which prescribes that an insurer may elect to recognize changes in the fair value of derivative instruments purchased to hedge indexed products in the statement of operations. The Company has elected to apply Bulletin 06-01 to its futures, variance swaps and total return swaps, which resulted in an increase of \$1.2 million and a decrease of \$1.5 million to the Company's net income for the three months ended March 31, 2019 and for the year ended December 31, 2018, respectively. Application of Bulletin 06-01 does not impact the Company's statutory surplus amounts.

In 2009, the Commissioner of the Division promulgated lowa Administrative Code (IAC) Section 191-97, Accounting for Certain Derivative Instruments Used to Hedge the Growth in Interest Credited for Indexed Insurance Products and Accounting for the Indexed Insurance Products Reserve, which prescribes that an insurer may elect (i) to use an amortized cost method to account for certain derivative instruments, such as call options, purchased to hedge the growth in interest credited to the customer on indexed insurance products and (ii) to utilize an indexed annuity reserve calculation methodology under which call options associated with the current index interest crediting term are valued at zero. The Company has elected to apply IAC Section 191-97 to its over the counter (OTC) call options and reserve liabilities. As a result, the Company's net income increased by \$50.3 million and decreased by \$182.3 million for the three months ended March 31, 2019 and for the year ended December 31, 2018, respectively, and the Company's statutory surplus decreased by \$17.0 million and increased by \$38.7 million as of March 31, 2019 and December 31, 2018, respectively.

The NAIC requires annuities issued by life insurance companies on or after January 1, 2015, to use the 2012 Individual Annuity Reserving (IAR) Mortality Table. In 2015, the Division promulgated IAC Section 43.3(5), which set an elective alternative effective date of January 1, 2016 for adoption of the 2012 IAR Mortality Table. The Company chose to use the Annuity 2000 Mortality Table for all annuities issued in 2015, which resulted in an increase of \$0.5 million and \$0.6 million to the Company's net income for the three months ended March 31, 2019 and for the year ended December 31, 2018, respectively. The Company's statutory surplus increased by \$3.8 million and \$3.3 million as of March 31, 2019 and December 31, 2018, respectively.

A reconciliation of the Company's net income and statutory surplus between practices prescribed or permitted by the State of Iowa and NAIC SAP is shown below:

	SSAF #	F/S Page	F/S Line #	March 31, 2019	December 31, 2018
NET IN	COME				
(1)	State basis (Page 4, Line 35, Columns 1 & 3)	XXX	XXX	36,530,800	80,635,223
(2)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP:				
	Derivative Instruments Bulletin 06-0186	4	38	1,180,281	(1,482,864)
	Derivative Instruments and Equity Indexed Reserves IAC 191-9786, 54	2, 3	7, 1	50,291,113	(182,324,925)
	2012 IAR Mortality Table for Annuities Issued in 2015 IAC 43.3(5)51	3	1	524,247	604,857
(3)	State Permitted Practices that are an increase/(decrease) from NAIC SAP:				
(4)	NAIC SAP (1-2-3=4)	XXX	XXX	(15,464,840)	263,838,155
SURPI	LUS				
(5)	State basis (Page 3, Line 38, Columns 1 & 2)	XXX	XXX	1,247,951,453	1,234,163,823
(6)	State Prescribed Practices that are an increase/(decrease) from NAIC SAP:				
	Derivative Instruments and Equity Indexed Reserves IAC 191-9786, 5	2, 3	7, 1	(16,950,868)	38,699,504
	2012 IAR Mortality Table for Annuities Issued in 2015 IAC 43.3(5)51	3	1	3,803,786	3,279,539
(7)	State Permitted Practices that are an increase/(decrease) from NAIC SAP:				
(8)	NAIC SAP (5-6-7=8)				

- B. Use of Estimates in the Preparation of the Financial Statements: No Change
- C. Accounting Policy
  - (1) No Change
  - (2) Bonds, other than loan-backed and structured securities, are stated at amortized cost or fair value based on their rating by the NAIC. Bonds held at amortized cost are amortized or accreted using the scientific interest method on a yield-to-worst basis.
  - (3) (5) No Change
  - (6) Loan-backed and structured securities are stated at amortized cost or fair market value based on their rating by the NAIC. Changes to estimated cash flows on the securities are accounted for retrospectively for securities that are highly rated at the time of purchase and in which the security cannot be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. The prospective method is used for those securities where an other than temporary impairment has been taken, the security is not highly rated at the time of purchase, securities where receipt of all contractual principal cash flows is not expected, or those securities that can be contractually prepaid or settled in such a way that the Company would not recover substantially all of the recorded investment. Loan-backed and structured securities stated at amortized cost are amortized or accreted using the scientific interest method.
  - (7) (13) No Change

#### D. Going Concern

Management's assessment of the relevant conditions through May 14, 2019 do not give rise to substantial doubt of the Company's ability to continue as a going concern.

#### Note 2. Accounting Changes and Corrections of Errors

During the current year's financial statement preparation, the Company discovered an error within prior period Annual Statements relating to reserves. After consideration of materiality and in accordance with SSAP No. 3, *Accounting Changes and Correction of Errors*, the correction was recorded directly to surplus. The impact of the correction of reserves decreased surplus by \$2.5 million in 2019. The impact of these amounts represented less than 1% of ending capital and surplus as of both March 31, 2019 and December 31, 2018.

#### Note 3. Business Combinations and Goodwill: No Change

#### Note 4. Discontinued Operations: NONE

#### Note 5. Investments

#### A - C. No Change

#### D. Loan-Backed Securities

- (1) Prepayment assumptions for loan-backed bonds and structured securities were obtained from broker dealer survey values or internal estimates
- (2) No other-than-temporary impairment was recognized on loan-backed securities due to the intent to sell or inability or lack of intent to retain the investment for a period of time sufficient to recover the amortized cost basis.
- (3) Other-than-temporary impairment was recognized on the following loan-backed securities due to the present value of the cash flows expected to be collected being less than the amortized cost basis:

1	2	3	4	5	6	7
	Book/Adjusted					Date of
	Carrying Value		Recognized	Amortized Cost		Financial
	Amortized Cost	Present Value of	Other-Than-	After Other-Than-		Statement
	Before Current	Projected Cash	Temporary	Temporary	Fair Value at	Where
CUSIP	Period OTTI	Flows	Impairment	Impairment	time of OTTI	Reported
05946X-QS-5	2,158,321	, ,	*	2,113,843	, ,	
12667G-XA-6	, ,	, ,	*	2,916,913	, ,	
38375B-7Z-9	544,260	520,158	24,101	520,158	520,158	03/31/2019
38375B-SB-9	,	,	*	957,435		
38376R-NN-2	2,310,984	2,264,943	46,041	2,264,943	2,219,427	03/31/2019
38376R-SY-3	3,267,257	3,197,701	69,555	3,197,701	3,171,402	03/31/2019
38376R-VB-9	4,890,731	4,847,095	43,635	4,847,095		
45660L-T4-1	5,986,101	5,959,730	26,371	5,959,730		03/31/2019
61762B-AU-9	, ,	, ,	*	10,333,557	, ,	03/31/2019
66704J-AC-2	4,640,740	4,576,161	64,579	4,576,161	4,564,500	03/31/2019
66704J-AG-3	29,879,692	29,750,308		29,750,308		
79548K-ZL-5	2,085,903	2,050,414	35,489	2,050,414	2,016,067	03/31/2019
86359L-HX-0	5,798,418	5,750,331	48,087	5,750,331	5,716,761	03/31/2019
86359L-QS-1	7,369,949	7,242,053	127,896	7,242,053	7,116,352	03/31/2019
92990G-AF-0	8,537,078	8,476,872	60,206	8,476,872	8,456,490	03/31/2019
Total	XXX	XXX	842,163	XXX	XXX	XXX

- (4) The following table shows the gross unrealized losses and fair values of loan-backed securities, which have not been impaired to fair value, aggregated by length of time that individual securities have been in a continuous unrealized loss position as of March 31, 2019.
  - a. The aggregate amount of unrealized losses:

h	Th	ne angregate related fair value of securities with unrealized losses.
	2.	12 Months or Longer
	1.	Less than 12 Months

b. The aggregate related fair value of securities with unrealized losses:

 1. Less than 12 Months
 3,880,860,735

 2. 12 Months or Longer
 1,097,570,035

(5) A full analysis of all relevant qualitative considerations was completed in reaching the conclusion that the impairments were not other-than-temporary, including the intent and ability to hold the investment for a period of time sufficient to allow for a recovery in value. Specific events that may influence the operations of the issuer and impaired earnings potential are reviewed in addition to length of time and extent to which the fair value has been less than cost.

#### E - R. No Change

Note 6. Joint Ventures, Partnerships and Limited Liability Companies: No Change

Note 7. Investment Income: No Change

#### Note 8. Derivative Instruments

A – G. No Change

H. There were no derivative contracts with premium cost.

Note. 9. Income Taxes: No Change

#### Note 10. Information Concerning Parent, Subsidiaries, Affiliates and Other Related Parties

Some employees of Athene Employee Services LLC participate in one or more Share Award Agreements (the Agreements) sponsored by Athene Holding, Ltd. (AHL), an indirect parent of the Company, for which the Company has no legal obligation. Salary expense of Athene Employee Services LLC is partially allocated to the Company through the Shared Services Agreement. Under SSAP No. 104R, Share-Based Payments, the stock compensation expense associated with the Agreements that would have been allocated to the Company is required to be recorded as a capital contribution to the reporting entity. The Company has allocated the stock compensation expense associated with the Agreements based on the same methodology as the Shared Services Agreement. In accordance with SSAP No. 104R, the Company incurred expense and recorded a capital contribution under the Agreements totaling \$1.6 million and \$9.1 million for the three months ended March 31, 2019 and for the year ended December 31, 2018, respectively, which includes amounts contributed by the Company to downstream insurance subsidiaries.

During July 2018, the Company received a \$15.0 million capital contribution from its direct parent, Athene Annuity & Life Assurance Company, and the Company made a \$15.0 million capital contribution to its wholly-owned subsidiary, Athene Annuity & Life Assurance Company of New York.

#### Note 11. Debt

- A. No Change
- Federal Home Loan Bank (FHLB) Agreements
  - (1) The Company is a member of the FHLB of Des Moines. Through its membership, the Company is eligible to borrow under variable rate short-term federal fund arrangements to provide additional liquidity. During 2018, the Company borrowed \$183.0 million from the FHLB through their variable rate short-term federal funds program, which was accounted for as borrowed money under SSAP No. 15, *Debt and Holding* Company Obligations. The borrowing matured on August 24, 2018 and carried an interest rate of 2.16%, with interest due at maturity. The Company incurred interest expense on the short-term borrowing of \$1.3 million for the year ended December 31, 2018. There were no borrowings outstanding under the short-term federal funds borrowing arrangement as of March 31, 2019.

The Company has issued funding agreements to the FHLB of Des Moines in exchange for cash resulting in a liability of \$913.7 million as of March 31, 2019. The Company uses these funds in an investment spread strategy, consistent with its other investment spread operations. As such, the Company applies SSAP No. 52, *Deposit-Type Contracts*, accounting treatment to these funds, consistent with its other deposit-type contracts. It is not part of the Company's strategy to utilize these funds for operations, and any funds obtained from the FHLB of Des Moines for use in general operations would be accounted for consistent with SSAP No. 15 as borrowed money.

The Company must provide appropriate collateral to borrow under the arrangements described above. The borrowing capacity available to the Company under these agreements is largely a factor of the Company's ability to post eligible collateral, as well as internal limits such as single-holder exposure limits (10% of the entity's balance sheet liabilities) and NAIC capital requirements.

The tables below indicate the amount of FHLB of Des Moines stock purchased, collateral pledged, assets and liabilities related to the agreements with FHLB of Des Moines.

(2) FHLB Capital Stock

Aggregate Totals			•
	1 Total 2+3	2 General Account	3 Sanarata Assaunta
I. Current Year	Total 2+3	General Account	Separate Accounts
(a) Membership Stock - Class A			
		10,000,000	
(b) Membership Stock - Class B			
(c) Activity Stock		37,048,000	
(d) Excess Stock			
(e) Aggregate Total (a+b+c+d)	47,048,000	47,048,000	
(f) Actual or estimated Borrowing Capacity as Determined by the			
Insurer	1,500,000,000	XXX	XXX
2. Prior Year-end			
(a) Membership Stock - Class A			
(b) Membership Stock - Class B		10,000,000	
(c) Activity Stock	37,048,000	37,048,000	
(d) Excess Stock			
(e) Aggregate Total (a+b+c+d)	47,048,000	47,048,000	
(f) Actual or estimated Borrowing Capacity as Determined by the			

11B(2)a2(f) should be equal to or greater than 11B(4)a2(d) b. Membership Stock (Class A and B) Eligible and Not Eligible for Redemption

		1	2	Eligible for Redemption			
		Current Year		3	4	5	6
		Total (2+3+4+5+6)	Not Eligible for Redemption	Less Than 6 Months	6 Months to Less Than 1 Year	1 to Less Than 3 Years	3 to 5 Years
Ме	mbership Stock						
1.	Class A						
2.	Class B	10.000.000	10,000,000				

11B(2)b1 Current Year Total (Column 1) should equal 11B(2)a1(a) Total (Column 1)

<sup>11</sup>B(2)b2 Current Year Total (Column 1) should equal 11B(2)a1(b) Total (Column 1)

	Collateral Pledged to FHLB a. Amount Pledged as of Reporting Date				
			1	2	3 Aggregate Total
	10 17 7110 1 10 1		Fair Value	Carrying Value	Borrowing
	Current Year Total General and Separate Collateral Pledged (Lines 2+3)		1 394 040 730	1,347,815,722	926.200.000
	Current Year General Account Total Coll			,- ,,	
	Current Year Separate Accounts Total C	•		,- ,,	
	4. Prior Year-end Total General and Separa	•			,,,
	Collateral Pledged		1,256,829,839	1,220,540,486	926,200,000
	11B(3)a1 (Columns 1, 2 and 3) should be e 11B(3)a2 (Columns 1, 2 and 3) should be e 11B(3)a3 (Columns 1, 2 and 3) should be e 11B(3)a4 (Columns 1, 2 and 3) should be e	equal to or less than 11B( equal to or less than 11B(	(3)b2 (Columns 1, 2 and 3 (3)b3 (Columns 1, 2 and 3	3 respectively) 3 respectively)	
	b. Maximum Amount Pledged During Reporting	Period			
			1	2	_3
					Amount Borrowed at Time of Maximum
			Fair Value	Carrying Value	Collateral
	Current Year Total General and Separate	e Accounts Maximum			
	Collateral Pledged (Lines 2+3)		1,394,040,730	1,347,815,722	926,200,000
	2. Current Year General Account Maximum	Collateral Pledged	1,394,040,730	1,347,815,722	
	3. Current Year Separate Accounts Maximu	um Collateral Pledged			926,200,000
	4. Prior Year-end Total General and Separa				
	Collateral Pledged		1,256,829,839	1,220,540,486	926,200,000
)	Borrowing from FHLB				
	a. Amount as of Reporting Date				
		1	2	3	4
		Total 2+3	General Account	Separate Accounts	Funding Agreements Reserves Established
	1. Current Year	Total 2+3	General Account	Separate Accounts	iveserves Established
	(a) Debt				XXX
	(b) Funding Agreements				913,686,405
	(c) Other				
	(d) Aggregate Total (a+b+c)	926,200,000		926,200,000	913,686,405
	0. D.:				
	2. Prior Year-end				V////
	(a) Debt				
	(b) Funding Agreements			,,	- , ,
	(c) Other(d) Aggregate Total (a+b+c)			926 200 000	912,994,994
	b. Maximum Amount During Reporting Period (	Current Year)	1	2	2
			Total 2+3	General Account	3 Separate Accounts
	1. Debt			<u>General 7 (Gooding</u>	
	Funding Agreements				926,200,000
	3. Other				
	4. Aggregate Total (Lines 1+2+3) 11B(4)b4 (Columns 1, 2 and 3) should be e		926,200,000		
	c. FHLB - Prepayment Obligations				
	. , ,		Does the company		
			have prepayment		
			obligations under the following		
			arrangements		
	1. Debt		arrangements (YES/NO)?		
	Debt     Funding Agreements		arrangements (YES/NO)? NO		

## Note 12. Retirement Plans, Deferred Compensation, Postemployment Benefits and Compensated Absences and Other Postretirement Benefit Plans

The Company has deferred compensation plans for agents which are not funded by the Company. The liability for these plans is included on Page 3, Line 21. These plans were frozen as of December 31, 2016. During February 2019, the Company paid out \$41.8 million of the liability.

#### Note 13. Capital and Surplus, Shareholders' Dividend Restrictions and Quasi-Reorganizations: No Change

#### Note 14. Liabilities, Contingencies and Assessments

#### A – E. No Change

#### F. All Other Contingencies

The Company and certain of its insurance subsidiaries have experienced increased service and administration complaints related to the conversion and administration of the block of life insurance business acquired in connection with Athene Holding Ltd.'s acquisition of Aviva USA Corporation and reinsured to affiliates of Global Atlantic Financial Group Ltd. The life insurance policies included in this block have been and are currently being administered by AllianceOne, a subsidiary of DXC Technology Company, which was retained by such Global Atlantic affiliates to provide services on such policies. AllianceOne also administers certain annuity policies that were on Aviva USA Corporation's legacy policy administration systems that were also converted in connection with the acquisition of Aviva USA Corporation and have experienced similar service and administration issues.

As a result of the difficulties experienced with respect to the administration of such policies, Athene received notifications from several state regulators, including but not limited to the New York Department of Financial Services (NYDFS), the California Department of Insurance and the Texas Department of Insurance, indicating, in each case, that the respective regulator planned to undertake a market conduct examination or enforcement proceeding of the Company or one of its subsidiaries, as applicable, relating to the treatment of policyholders subject to Athene reinsurance agreements with affiliates of Global Atlantic and the conversion of such annuity policies, including the administration of such blocks by AllianceOne. On June 28, 2018, Athene Life Insurance Company of New York (ALICNY) entered into a consent order with the NYDFS resolving that matter in a manner that ultimately did not have a material impact on its financial condition, when considering AHL's indemnification from affiliates of Global Atlantic, which was passed to ALICNY in the form of a capital contribution in the third quarter of 2018.

In addition to the foregoing, the Company has received inquiries, and expects to continue to receive inquiries, from other regulatory authorities regarding the conversion matter. In addition to the examinations and proceedings initiated to date, it is possible that other regulators may pursue similar formal examinations, inquiries or enforcement proceedings and that any examinations, inquiries and/or enforcement proceedings may result in fines, administrative penalties and payments to policyholders. The Company is not currently able to estimate the amount of any such fines, penalties or payments arising from these matters with reasonable certainty, but it is possible that such amounts may be material.

Pursuant to the terms of the reinsurance agreements between Athene and the relevant affiliates of Global Atlantic, the applicable affiliates of Global Atlantic have financial responsibility for the ceded life block and are subject to significant administrative service requirements, including compliance with applicable law. The agreements also provide for indemnification to Athene, including for administration issues.

On January 23, 2019, the Company received a letter from the NYDFS, with respect to a recent Pension Risk Transfer (PRT) transaction, which expressed concerns with the Company's interpretation and reliance upon certain exemptions from licensing in New York in connection with certain activities performed by employees in the PRT channel, including specific activities performed within New York. The Company is currently in discussions with the NYDFS to identify approaches to resolve its concerns. Any losses cannot be reasonably determined at this time.

In 2000 and 2001, two insurance companies which were subsequently merged into the Company purchased from American General Life Insurance Company (American General) broad based variable corporate-owned life insurance (COLI) policies that, as of March 31, 2019, had an asset value of \$372.7 million. In January 2012, the COLI policy administrator delivered to the Company a supplement to the existing COLI policies and advised that American General and ZC Resource Investment Trust (ZC Trust) had unilaterally implemented changes set forth in the supplement that if effective, would: (1) potentially negatively impact the crediting rate for the policies and (2) change the exit and surrender protocols set forth in the policies. In March 2013, the Company filed suit against American General, ZC Trust, and ZC Resource LLC in Chancery Court in Delaware, seeking, among other relief, a declaration that the changes set forth in the supplement were ineffectual and in breach of the parties' agreement. The parties filed cross motions for judgment as a matter of law, and the court granted defendants' motion and dismissed without prejudice on ripeness grounds. The issue that negatively impacts the crediting rate for one of the COLI policies has subsequently been triggered and on April 3, 2018, the Company filed its suit against the same defendants in Chancery Court in Delaware seeking substantially similar relief, which defendants have moved to dismiss and the Company has opposed. The Court heard oral arguments on February 13, 2019 and has taken the matter under advisement. If the supplement is ultimately deemed to be effective, the purported changes to the policies could impair the Company's ability to access the value of guarantees associated with the policies. The value of the guarantees included within the asset value reflected above is \$184.6 million as of March 31, 2019.

On April 6, 2016, the U.S. Department of Labor (DOL) issued the fiduciary rule which imposes upon third parties who sell annuities within Employee Retirement Income Security Act of 1974 (as amended, ERISA) plans or to individual retirement account (IRA) holders a fiduciary duty to retirement investors. On June 21, 2018, the Fifth Circuit Court of Appeals issued a mandate officially vacating as a whole the DOL's 2016 Fiduciary Rule.

The U.S. Securities and Exchange Commission (SEC) has indicated that it will work with the DOL to propose rules creating a uniform standard of conduct applicable to broker-dealers and investment advisers in 2019, which, if adopted, may affect the distribution of the Company's products. The NAIC is working to propose changes to the Suitability in Annuity Transactions Model Regulation and some states separately are updating their suitability regulations to include the best interest concept. Should the SEC, NAIC, or state specific rules, once adopted, not align, the distribution of the Company's products could be further complicated.

In addition to the cases previously discussed, the Company is routinely involved in litigation and other proceedings, reinsurance claims and regulatory proceedings arising in the ordinary course of its business. At present, no contingencies related to pending litigation and regulatory matters are considered material in relation to the financial position of the Company.

- Note 15. Leases: NONE
- Note 16. Information about Financial Instruments with Off-Balance Sheet Risk and Financial Instruments with Concentrations of Credit Risk: No Change
- Note 17. Sale, Transfer and Servicing of Financial Assets and Extinguishment of Liabilities: NONE
- Note 18. Gain or Loss to the Reporting Entity from Uninsured Plans and the Uninsured Portion of Partially Insured Plans: NONE
- Note 19. Direct Premium Written/Produced by Managing General Agents/Third Party Administrators: NONE
- Note 20. Fair Value Measurements

Α.

(1) Fair value measurements at reporting date

Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
a. Assets at fair value					
Bonds: Corporates		173,557			173,557
Bonds: Exchange traded funds		27,630,000			27,630,000
Bonds: CMBS		6,110			6,110
Bonds: RMBS		571,384			571,384
Common stocks unaffiliated					
Derivative assets: Currency swaps		3,053,751			3,053,751
Derivative assets: Interest rate swaps					
Derivative assets: Total return swaps		3,850,249			3,850,249
Derivative assets: Futures	5,739,353				5,739,353
Derivative assets: Forwards		3,709,319			3,709,319
Separate account assets: Variable products		31,278,718			31,278,718
Total assets at fair value	51.134.075	117.322.112	2.441.642		170.897.829

Description for each class of asset or liability	(Level 1)	(Level 2)	(Level 3)	Net Asset Value (NAV)	Total
b. Liabilities at fair value					
Derivative liabilities: Variance swaps		189,570			189,570
Derivative liabilities: Options		943,340			943,340
Derivative liabilities: Futures					
Derivative liabilities: Forwards		267,254			267,254
Separate account liabilities: Variable products		31,278,565			31,278,565
Total liabilities at fair value	1,109,891	32,678,729			33,788,620

There were no transfers between Level 1, Level 2, or Level 3 of the fair value hierarchy during the quarter ended March 31, 2019.

(2) Fair value measurements in (Level 3) of the fair value hierarchy

	Beginning	Transfers	Transfers	Total gains and (losses)	Total gains and (losses)					Ending
Description for each class of	Balance at	into	out of	included in	included in					Balance at
asset or liability	01/01/2019	Level 3	Level 3	Net Income	Surplus	Purchases	Issuances	Sales	Settlements	03/31/2019
a. Assets										
Common stocks unaffiliated	2,489,736				(48,094)					2,441,642
Total Assets	2,489,736				(48,094)					2,441,642

- (3) Transfers between fair value hierarchy levels are recognized at the end of the period in which the transfer occurs.
- (4) The following discussion describes the valuation methodologies and inputs used for assets and liabilities measured and disclosed at fair value. The techniques utilized in estimating the fair values of financial instruments are reliant on the assumptions used.

Fair value estimates are based on quoted market prices when available. When quoted market prices are not available, the Company utilizes commercially available pricing vendors that utilize observable market inputs, like recent trading activity, to derive fair value. When vendor prices are not available, fair value is generally estimated using discounted cash flow analyses, incorporating current market inputs for similar financial instruments with comparable terms and credit quality (matrix pricing). In instances where there is little or no market activity for the same or similar instruments, the Company estimates the fair value using methods, models and assumptions that management believes market participants would use to determine a current transaction price. These valuation techniques involve some level of management estimation and judgment which becomes significant with increasingly complex instruments or pricing models. Where appropriate, adjustments are included to reflect risk inherent in a particular methodology, model or input employed.

The Company's financial assets and liabilities carried at estimated fair value have been classified, for disclosure purposes, based on a hierarchy defined by current accounting guidance. The hierarchy gives the highest ranking to fair values determined using unadjusted quoted prices in active markets for identical assets and liabilities (Level 1) and the lowest ranking to fair values determined using methodologies and models with unobservable inputs (Level 3). An asset's or a liability's classification is based on the lowest level input that is significant to its measurement. For example, a Level 3 fair value measurement may include inputs that are both observable (Levels 1 and 2) and unobservable (Level 3).

The levels of the fair value hierarchy are as follows:

Level 1 - Unadjusted quoted prices for identical assets or liabilities in an active market.

Level 2 - Quoted prices for inactive markets or valuation techniques that require observable direct or indirect inputs for substantially the full term of the asset or liability.

Level 2 inputs include the following:

- 1. Quoted prices for similar assets or liabilities in active markets,
- 2. Observable inputs other than quoted market prices, and
- 3. Observable inputs derived principally from market data through correlation or other means.

Level 3 - Prices or valuation techniques with unobservable inputs significant to the overall fair value estimate. These valuations use critical assumptions not readily available to market participants. Level 3 valuations are based on market standard valuation methodologies, including discounted cash flows, matrix pricing, or other similar techniques.

Assets and liabilities are valued as discussed below in part C.

- B. Other Fair Value Disclosures: NONE
- C. Aggregate fair value for all financial instruments and the level within the fair value hierarchy in which the fair value measurements in their entirety fall.

	Aggregate					Net Asset	Not Practicable
Type of Financial Instrument	Fair Value	Admitted Assets	(Level 1)	(Level 2)	(Level 3)	Value (NAV)	(Carrying Value)
Assets - Bonds	38,817,822,906	37,604,022,335	5,348,665	37,088,729,681	1,723,744,560		
Assets - Preferred stocks							
Assets - Common stocks unaffiliated	94,879,643	94,879,643	45,388,977	47,049,024	2,441,642		
Assets - Mortgage loans - first liens							
Assets - Mortgage loans - other than first liens	1,677,082,296	1,672,454,540			1,677,082,296		
Assets - Policy loans	188,393,597	188,393,597		188,393,597			
Assets - Cash and short-term investments	1,842,142,007	1,842,143,492	1,840,151,931	1,990,076			
Assets - Derivative assets							
Assets - Derivative collateral assets	26,945,866	26,945,866	26,945,866				
Assets - Other invested assets	2,059,155,285	2,054,194,307		393,906,678	128,215,910	. 1,537,032,697	
Assets - Separate account: variable products	31,278,718	31,278,718		31,278,718			
Assets - Separate account: group annuity	6,878,288,329	6,789,232,687	154,640,344	5,868,591,182	829,409,833	25,646,970	
Liabilities - Deposit-type contracts	438,638,337	418,417,045			438,638,337		
Liabilities - Derivative liabilities	63,588,660	25,359,322	12,636,403	47,078,654	3,873,603		
Liabilities - Derivative collateral liability	1,523,142,195	1,523,142,195	1,523,142,195				
Liabilities - Separate account: group annuity deposit-							
type contracts	649,832	661,788			649,832		

Bonds and short-term investments – The Company obtains the fair value for most marketable, public bonds without an active market from several commercial pricing services. These are classified as Level 2 assets. The pricing services incorporate a variety of market observable information in their valuation techniques, including benchmark yields, broker-dealer quotes, credit quality, issuer spreads, bids, offers, and other reference data. If the Company cannot value a public bond with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3. The Company values privately placed bonds based on the credit quality and duration of comparable marketable securities, which may be securities of another issuer. In some instances, the Company uses a matrix-based pricing model. These models consider the current level of risk-free interest rates, corporate spreads, credit quality of the issuer, and cash flow characteristics of the security. Privately placed fixed maturity securities are classified as Level 2 or 3.

Preferred stocks and common stocks unaffiliated – The Company values equity securities, typically private equities or equity securities not traded on an exchange, using several commercial pricing services or an internal model. The securities priced by a commercial pricing service are classified as Level 2 and the securities priced by an internal model are classified as Level 3. In addition, unaffiliated common stocks include FHLB stock, which is carried at fair value, which is presumed to be par because it can only be redeemed by the bank and is classified as Level 2.

Mortgage loans – The Company estimates mortgage loans on a monthly basis using discounted cash flow analysis and rates being offered for similar loans to borrowers with similar credit ratings. Loans with similar characteristics are aggregated for purposes of the calculations. The discounted cash flow model uses unobservable inputs, including estimates of discount rates and loan prepayments. Mortgage loans are classified as Level 3.

Policy loans – The fair value of policy loans classified as Level 2 is equal to the carrying value of the loans, which are collateralized by the cash surrender value of the associated insurance contracts.

Derivatives – Derivative contracts can be exchange traded or over-the-counter. Over-the-counter derivatives are valued using valuation models or an income approach using third-party broker valuations. Valuation models require a variety of inputs, including contractual terms, market prices, yield curves, measures of volatility, prepayment rates, and correlation of the inputs. The Company considers and incorporates counterparty credit risk in the valuation process through counterparty credit rating requirements and monitoring of overall exposure. The Company also evaluates and includes its own nonperformance risk in valuing derivatives. The majority of the Company's derivatives trade are in liquid markets; therefore, the Company can verify model inputs and model selection does not involve significant management judgment and are classified within Level 2. If the Company cannot verify model inputs and model selection does involve significant management judgment, the derivatives are classified as Level 3.

Other invested assets – Within other invested assets, partnerships are valued based on net asset value information provided by the general partner or related asset manager. These partnership interests usually include multiple underlying investments for which either observable market prices or other valuation methods are used to determine the fair value. These investments are reported in the Net Asset Value (NAV) column. Other than partnerships, other invested assets may include surplus notes and other investments with bond or stock characteristics and the Company attempts to value these using several commercial pricing services, which would be classified as Level 2 assets. If the Company cannot value with a commercial pricing vendor, the Company obtains broker quotes (or utilizes an internally-developed model) and are considered to be Level 3 assets.

Separate account assets (variable products) – Separate account assets classified as Level 2 are valued based on the fair value of the underlying funds. Fair values and changes in the fair values of the underlying funds accrue directly to the policy owners and are not included in the Company's revenues and expenses or surplus.

Separate account assets (group annuity) – Financial instruments within this separate account classified as Level 2 and 3 or included in the NAV column are valued using the same fair value assumptions and methods utilized in the general account.

Deposit-type contracts (including separate account group annuity) – Deposit-type contracts classified as Level 3 include single premium immediate annuities (SPIA) and supplemental contracts. Fair value of SPIA and supplemental contracts are calculated by discounting best estimate cash flows based on mortality and market interest rate assumptions.

D. Not Practicable to Estimate Fair Value: NONE

E. Net Asset Value

The Company invests in certain non-fixed income, alternative investments in the form of limited partnerships (investment funds) which are reported at NAV. Adjustments to the carrying amount reflect the Company's pro rata ownership percentage of the operating results as indicated by NAV in the investment fund financial statements. The NAV from the investment fund financial statements can be on a lag of up to three months when investee information is not received in a timely manner. These investments are listed in the NAV column of the fair value tables above as this is the primary method for reporting fair value for these investments.

As of March 31, 2019, the Company has \$978.9 million unfunded commitments to invest in these investment funds.

#### Note 21. Other Items: No Change

#### Note 22. Events Subsequent

Subsequent events have been considered through May 14, 2019 for the statutory statement dated March 31, 2019. There have been no Type I or Type II events subsequent to the close of the books and accounts for this statement that have a material effect on the financial condition of the Company.

Note 23. Reinsurance: No Change

Note 24. Retrospectively Rated Contracts & Contracts Subject to Redetermination: NONE

Note 25. Change in Incurred Losses and Loss Adjustment Expenses: NONE

Note 26. Intercompany Pooling Arrangements: NONE

Note 27. Structured Settlements: NONE

Note 28. Health Care Receivables: NONE

Note 29. Participating Policies: No Change

Note 30. Premium Deficiency Reserves: NONE

Note 31. Reserves for Life Contracts and Annuity Contracts: No Change

Note 32. Analysis of Annuity Actuarial Reserves and Deposit Type Liabilities by Withdrawal Characteristics: No Change

Note 33. Premium and Annuity Considerations Deferred and Uncollected: No Change

#### Note 34. Separate Accounts

During 2019, the Company formed Athene Annuity and Life Company WY Group Annuity Dedicated Separate Account, an insulated dedicated separate account that will support annuities payable under group fixed annuity contracts issued to an employer, in respect of the employer's pension plan. The group fixed annuity contracts obligate the Company's general account to make annuity payments if the separate account is not able to do so. As of March 31, 2019, this separate account had assets of \$1.6 billion.

Note 35. Loss/Claim Adjustment Expenses: NONE